Becton Dickinson opened higher at $199.77, compared with its previous close of $198.34. In the last trading session, the stock traded between $197.35 and $199.94. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Becton Dickinson is now worth
$ 82.90
resulting in a loss of
$ 17.10 (17.10%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
+$0.28 (+0.14%)
Day High
$199.94
Day Low
$197.35
Day Open
$199.77
Prev Close
$198.34
Volume
3,95,299
1W Return
-0.87%
1M Return
9.12%
3M Return
17.96%
6M Return
36.69%
1Y Return
9.42%
Market Cap ($ Mn)
54,102
PE Ratio
44.07
PB Ratio
2.11
PEG Ratio
7.32
ROE
6.60%
ROCE
5.21%
EPS (TTM)
-
1 Week
-0.87%
1 Month
9.12%
3 Months
17.96%
6 Months
36.69%
9 Months
-1.23%
Barclays initiates Becton Dickinson with Underweight rating, $165 target
Barclays initiated coverage on Becton Dickinson with an Underweight rating. Price target set at $165 by analyst Christopher Pasquale. No additional financial data or operational commentary provided in the note.
22 days agoBecton Dickinson appoints Ferass Abuzaina as worldwide president of Surgery
Ferass Abuzaina appointed worldwide president of Surgery effective immediately. Reports to Peter Menziuso, president of Interventional segment. Previously served as Worldwide VP/GM for Advanced Repair and Reconstruction.
24 days agoBD raises US investment to $19 billion in government partnership
Becton Dickinson commits $19 billion to US manufacturing under new government partnership. Deal includes $3 billion specific to manufacturing expansion and tariff relief under Section 232. Domestic production of essential medical consumables to rise by 5 billion units annually. 100 percent of needles used in America will be manufactured domestically using US steel.
24 days agoBecton Dickinson Q3FY26 Results: Revenue up 4.4% to $5 billion, EPS rises
Revenue reached $5 billion, up 4.4% YoY, with over 90% of portfolio growing high single digits. Adjusted EPS rose 4.9% to $3.23, prompting an increase in full-year EPS guidance midpoint. Biopharma Systems grew 5.2%, driven by double-digit GLP-1 demand despite vaccine headwinds. Adjusted operating margin declined 130 bps to 24.9%, largely due to ~110 bps tariff impact. Year-to-date free cash flow surged 45% to $1.7 billion, supported by improved working capital.
25 days agoBD deploys first US pharmacy automation robot Vmax 160 at Fairview
BD deploys its first US pharmacy automation robot, the Vmax 160, at Fairview Health Services. Fairview fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies. The Vmax 160 features 99.8% loading accuracy and supports cold-chain storage at 2–8°C. The system addresses growing demand for specialty therapies like GLP-1s and biologics.
1mo agoBD stock rises 3% despite FDA recall alert for sodium chloride ampules
Becton Dickinson shares rose 3% to $186.23 on Wednesday, defying a concurrent FDA alert regarding recalled sodium chloride ampules in surgical kits. The stock trades well above its 200-day moving average, though an RSI of 74 suggests overbought conditions. Analysts maintain a Buy consensus with an average target of $184.20.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Becton Dickinson is now worth
$ 82.90
resulting in a loss of
$ 17.10 (17.10%)
Note: Past profits do not guarantee future returns.
